Education

Educational corner

October 30, 2024

E-learning

CHALLENGING THE CONVENTIONAL IN IBD TREATMENT

Overall course objective: Update healthcare professionals with an interest in inflammatory bowel disease (IBD) on the use of selective granulocyte and monocyte apheresis with Adacolumn® as an adjuvant therapy in its management. Understand the immunomodulatory mechanism of action of Adacolumn® and its scientific basis in controlling intestinal inflammation, as well as to identify the profiles […]

February 1, 2024

E-learning

CurQD®: The first botanical product for IBD

January 30 | 2024 The international experts in gastroenterology and integrative medicine who developed CurQD® for the treatment of Inflammatory Bowel Disease, Prof. Shomron Ben-Horin and Nir Salomon, share with all of us both the properties of the components of CurQD®, Qing Dai and curcumin (Qura), as well as the main scientific studies thathave demonstrated […]

January 31, 2024

E-learning

Adacolumn®: Fostering Synergies, Reducing Risks

Dr. Rodríguez-Lago shares existing evidence of the crucial role played by innate immunity in the pathogenesis of Inflammatory Bowel Disease (IBD), as well as in the failure of advanced therapies such as biologic drugs and small molecules. Hence, the combined use of granulocyte and monocyte apheresis (GMA, Adacolumn®) targeting mainly innate IBD trigger cells, such […]

role of GMA in IBD

February 6, 2023

E-learning

The role of therapeutic apheresis in the management of IBD

The main objectives of this webinar are: clarify what is needed to have the best treatment outcome for IBD patients, how to help them maintain control of their disease and how Adacolumn’s mechanism of action might contribute to achieving both, alone or in combination with other therapies. Dr. Alessandro Mazzoni. (A.O.U. Pisana) Dra. Irene Bianco. […]

April 26, 2022

E-learning

GMA use in paediatric IBD patients: Real world experiences (in English)

The paediatric inflammatory bowel disease (IBD) can cause malnutrition and growth retardation. Patients with IBD will require life-long treatment but can be limited by the potential adverse events of corticosteroids and anti-TNF agents in children as well as secondary loss of response (LoR) and drug dependence can occur at some time during the lifetime. Experience […]

Contact UsFor more information

Contact Us